Biopathology and Liquide Biopsy Platform (BLBL)

Activity area(s)

The Biopathology/LB platform (BLBL) develops different methodologies and technologies such as pyrosequencing, Sanger sequencing, and Next Generation Sequencing from tissue and biological (circulating free DNA) samples, tissue microarrays (TMAs), CellSearch and ISET/Screen cells technologies for circulating tumour cell detection and characterization, laser capture microdissection, virtual digital imaging, immunolabeling and automatized in situ hybridization system, qPCR, Agilent technology for arrays lectures


The Biopathology and LBL platform is certified according to the S96-900 norm. This platform is located in a specific part of the Laboratory of Clinical and Experimental Pathology and has been recognized to be a platform of the Canceropôle PACA in 2012. The team working on this platform associates some biopathologists, some ingeniors and lab technicians, as well as biostatisticians and bioinformaticians


Paul Hofman

Type of structure

Nice Hospital

Recognition by

University of Nice Sophia Antipolis


Pasteur Hospital Pavillon J 30 av de la voie romaine Nice

Contact name

Paul Hofman

Contact mail

Skills of the team members

  • Ilie Marius
  • Hofman Paul
  • Lespinet Virginie
  • Bordone Olivier
  • Ribeyre Camille
  • Fayada Julien
  • Lalvée Salomé MD, PhD, HDR
  • MD, PhD, HDR
  • PhD, Molecular Biology, Ingenior
  • MSs, Molecular Biology, Ingenior
  • MSc, Bioinformatician, Ingenior
  • MSc, CTC platform, Ingenior
  • MSc, Molecular Biology, Technicien

Five top/relevant papers in the last five years related to the platform activity

Ilie M, Nunes M, Blot L, Hofman V, Long-Mira E, Butori C, Selva E, Merino-Trigo A, Vénissac N, Mouroux J, Vrignaud P, Hofman P. Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps. Cancer Med. 2015 Feb;4(2):201-11.

Ilie M, Hofman V, Long E, Bordone O, Selva E, Washetine K, Marquette CH, Hofman P. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med. 2014 Nov;2(11):107.

Ilie M, Hofman V, Long-Mira E, Selva E, Vignaud JM, Padovani B, Mouroux J, Marquette CH, Hofman P. “Sentinel” circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One. 2014 Oct 31;9(10):e111597

Hofman V, Ilie M, Long E, Guibert N, Selva E, Washetine K, Mograbi B, Mouroux J, Vénissac N, Reverso-Meinietti J, Milano G, Mazières J, Marquette CH, Paterlini-Bréchot P, Hofman P. Detection of circulating tumor cells from lung cancer patients in the era of targeted therapy: promises, drawbacks and pitfalls. Curr Mol Med. 2014 May;14(4):440-56

Ilie M, Long E, Hofman V, Selva E, Bonnetaud C, Boyer J, Vénissac N, Sanfiorenzo C, Ferrua B, Marquette CH, Mouroux J, Hofman P. Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer. Br J Cancer. 2014 Mar 4;110(5):1236-43

Contribution to the FHU

WP1 and WP2